Literature DB >> 26974890

Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis.

Louvina E van der Laan1, H Simon Schaaf, Regan Solomons, Marianne Willemse, Nabil Mohamed, Sandika O Baboolal, Anneke C Hesseling, Ronald van Toorn, Anthony J Garcia-Prats.   

Abstract

Fluoroquinolones are a key component of multidrug-resistant tuberculosis treatment. We describe the first reported case of probable levofloxacin-associated intracranial hypertension in a 6-year-old girl with pulmonary multidrug-resistant tuberculosis. The case highlights the potential risk of secondary intracranial hypertension in multidrug-resistant tuberculosis patients who require prolonged fluoroquinolone therapy and the need for ophthalmologic screening in children with suggestive signs and symptoms.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26974890     DOI: 10.1097/INF.0000000000001137

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  3 in total

1.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  Tuberculous Meningitis in Children: Reducing the Burden of Death and Disability.

Authors:  Julie Huynh; Yara-Natalie Abo; Karen du Preez; Regan Solomons; Kelly E Dooley; James A Seddon
Journal:  Pathogens       Date:  2021-12-30

3.  The epidemiological characteristics and profile of drug-resistant tuberculosis among children with tuberculosis in Sichuan, China, 2015-2018: A retrospective study.

Authors:  Yuanhong Xu; Qingfeng Li; Ma Zhu; Xueqi Wu; Dongmei Wang; Jia Luo; Yingjie Li; Jing Zhong; Peibin Zeng
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.